Trial Profile
Multi-centre, Adaptive, Randomized Trial of the Safety and Efficacy of Treatments of COVID-19 in Hospitalized Adults
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Apr 2024
Price :
$35
*
At a glance
- Drugs Cilgavimab/tixagevimab (Primary) ; Hydroxychloroquine (Primary) ; Interferon beta-1a (Primary) ; Interferon beta-1a (Primary) ; Lopinavir/ritonavir (Primary) ; Lopinavir/ritonavir (Primary) ; Remdesivir (Primary)
- Indications COVID-19 respiratory infection
- Focus Therapeutic Use
- Acronyms DisCoVeRy
- 05 Apr 2024 This trial has been completed in Portugal, according to European Clinical Trials Database record.
- 24 Nov 2023 Status changed from active, no longer recruiting to completed.
- 12 Sep 2023 This trial has been discontinued in Ireland, according to the European Clinical Trials Database record.